½ÃÀ庸°í¼­
»óǰÄÚµå
1493389

È¿¼Ò¸é¿ªÃøÁ¤¹ý ½ÃÀå ±Ô¸ð, Á¡À¯À², µ¿Ç⠺м® ¸®Æ÷Æ® : Á¦Ç°º°, ¿ëµµº°, °Ëüº°, ÃÖÁ¾ ¿ëµµº°, Áö¿ªº°, ºÎ¹®º° ¿¹Ãø(2024-2030³â)

Enzyme Immunoassay Market Size, Share & Trends Analysis Report By Product (Reagents & Kits, Software & Services), By Application (Oncology, Cardiology), By Specimen, By End-use, By Region, And Segment Forecasts, 2024 - 2030

¹ßÇàÀÏ: | ¸®¼­Ä¡»ç: Grand View Research | ÆäÀÌÁö Á¤º¸: ¿µ¹® 120 Pages | ¹è¼Û¾È³» : 2-10ÀÏ (¿µ¾÷ÀÏ ±âÁØ)

    
    
    




¡Ø º» »óǰÀº ¿µ¹® ÀÚ·á·Î Çѱ۰ú ¿µ¹® ¸ñÂ÷¿¡ ºÒÀÏÄ¡ÇÏ´Â ³»¿ëÀÌ ÀÖÀ» °æ¿ì ¿µ¹®À» ¿ì¼±ÇÕ´Ï´Ù. Á¤È®ÇÑ °ËÅ並 À§ÇØ ¿µ¹® ¸ñÂ÷¸¦ Âü°íÇØÁֽñ⠹ٶø´Ï´Ù.

È¿¼Ò¸é¿ªÃøÁ¤¹ý ½ÃÀå ¼ºÀå°ú µ¿Çâ :

Grand View Research, Inc.ÀÇ ÃֽЏ®Æ÷Æ®¿¡ µû¸£¸é ¼¼°èÀÇ È¿¼Ò¸é¿ªÃøÁ¤¹ý ½ÃÀå ±Ô¸ð´Â 2024-2030³â CAGR 3.9%·Î È®´ëÇϸç, 2030³â¿¡´Â 224¾ï 2,000¸¸ ´Þ·¯¿¡ ´ÞÇÒ °ÍÀ¸·Î ¿¹ÃøµÇ°í ÀÖ½À´Ï´Ù.

¸¸¼ºÁúȯ ¹× °¨¿°¼º ÁúȯÀÇ À¯Çà, ÇöÀå °Ë»ç¿¡ ´ëÇÑ ¼ö¿ä Áõ°¡, ÀÎ½Ä ¹× ÀÇ·áºñ ÁöÃâ Áõ°¡´Â ½ÃÀåÀ» ´õ¿í ÃËÁøÇÒ °ÍÀ¸·Î ¿¹»óµË´Ï´Ù. ¶ÇÇÑ ½ÃÀå ÁøÃâ±â¾÷ °£ÀÇ ÇÕÀÛ ÅõÀÚ ¹× Á¦Ç° Ãâ½Ã Áõ°¡, Á¤ºÎ ÅõÀÚ Áõ°¡µµ ½ÃÀå ¼ºÀå¿¡ ±àÁ¤ÀûÀÎ ¿µÇâÀ» ¹ÌÄ¥ °ÍÀ¸·Î ¿¹»óµË´Ï´Ù. ¿¹¸¦ µé¾î 2023³â 7¿ù Anbio Biotechnology Limited´Â POC(Point-Of-Care) ¸é¿ª Áø´ÜÀ» À§ÇÑ ÈÞ´ë¿ë ¼Ö·ç¼ÇÀÎ AF-100S FIA ¼Ö·ç¼Ç(AF-100S FIA Solution)À» Ãâ½ÃÇß½À´Ï´Ù. ÀÌ ºÐ¼®±â´Â ´Ù¾çÇÑ ºÐ¼® ´ë»ó È¿¼Ò¸¦ °ËÃâÇÒ ¼ö ÀÖÀ¸¸ç, ½Ã°£´ç ÃÖ´ë 240°ÇÀÇ °Ë»ç¸¦ ¼öÇàÇÒ ¼ö ÀÖ½À´Ï´Ù.

Á¤ºÎ ÅõÀÚ Áõ°¡´Â È¿¼Ò ¸é¿ª ÃøÁ¤ ±â¼ú ½ÃÀå ¼ºÀåÀ» Å©°Ô Áö¿øÇÒ °ÍÀ¸·Î ¿¹»óµË´Ï´Ù. Á¤ºÎ ÅõÀÚ´Â ÁÖ·Î °³¹ßµµ»ó±¹ÀÇ ÀÇ·á ÀÎÇÁ¶ó È®Ãæ¿¡ µµ¿òÀÌ µÉ °ÍÀÔ´Ï´Ù. ÀÌ·¯ÇÑ È®´ë´Â ÀÓ»ó ÇöÀå¿¡¼­ EIA ±â¼úÀÇ ±¤¹üÀ§ÇÑ Ã¤Åðú ÅëÇÕÀ» µ½°í Áúº´ÀÇ Á¶±â ¹ß°ß, ¸ð´ÏÅ͸µ ¹× °ü¸® ´É·ÂÀ» °­È­ÇÏ´Â µ¥ µµ¿òÀÌ µÉ °ÍÀÔ´Ï´Ù. ¶ÇÇÑ °¨¿°º´ ´ëÀÀ ¹× ¿¹¹æ ÇÁ·Î±×·¥ µî ´ë±Ô¸ð °ËÁø ¹× °¨½Ã Ȱµ¿¿¡ EIA¸¦ Ȱ¿ëÇÒ ¼ö ÀÖ´Â ±¹°¡ º¸°Ç ÇÁ·Î±×·¥ÀÇ ¼ö¸³À» ÃËÁøÇÒ ¼ö ÀÖ½À´Ï´Ù. ¿¹¸¦ µé¾î ¿µ±¹ Á¤ºÎ´Â 2022³â 3¿ù ¿¬±¸°³¹ß°ú »õ·Î¿î ±â±â ¹× Áø´Ü¾à »ý»êÀ» °­È­Çϱâ À§ÇØ 3¾ï 4,700¸¸ ´Þ·¯¸¦ ÅõÀÚÇÒ °ÍÀ̶ó°í ¹ßÇ¥Çß½À´Ï´Ù.

COVID-19 ÆÒµ¥¹ÍÀº ½ÃÀå¿¡ Å« ¿µÇâÀ» ¹ÌÃÆ½À´Ï´Ù. Àü¿°º´Àº EIA ŰƮ ¹× ½Ã¾àÀ» Æ÷ÇÔÇÑ ´Ù¾çÇÑ ÇコÄɾî Á¦Ç°°ø±Þ¸Á°ú Á¦Á¶ °øÁ¤¿¡ Àå¾Ö¸¦ ÀÏÀ¸Ä×½À´Ï´Ù. ÀÌ·¯ÇÑ È¥¶õÀº ºÀ¼â Á¶Ä¡, Àη ºÎÁ· ¹× ¹°·ù ¹®Á¦·Î ÀÎÇØ ¹ß»ýÇß½À´Ï´Ù. ±×·¯³ª COVID-19´Â SARS-CoV-2 Ç×ü °ËÃâÀ» À§ÇÑ EIA ±â¼úÀÇ °³¹ß ¹× äÅÃÀ» °¡¼ÓÈ­ÇÏ¿© ½ÃÀå¿¡ ¿µÇâÀ» ¹ÌÃÆ½À´Ï´Ù. ÀÌ·¯ÇÑ ¼ö¿ä ±ÞÁõÀÇ ¹è°æ¿¡´Â °¨¿°ÀÚ¸¦ ½Äº°ÇÏ°í ¹ÙÀÌ·¯½º È®»êÀ» ÆÄ¾ÇÇϱâ À§ÇÑ ´ë·® °Ë»çÀÇ Çʿ伺ÀÌ ÀÖ¾ú½À´Ï´Ù. ³ôÀº ƯÀ̼º°ú ¹Î°¨µµ·Î ¾Ë·ÁÁø È¿¼Ò ¸é¿ª ÃøÁ¤¹ýÀº Àü¿°º´ ÅðÄ¡¿¡ ÇʼöÀûÀÎ ÅøÀÌ µÇ¾úÀ¸¸ç, Ȱµ¿¼º °¨¿°À» Áø´ÜÇϰí Áý´Ü³» ¹ÙÀÌ·¯½º È®»ê Á¤µµ¸¦ Æò°¡ÇÏ´Â ¿¬±¸¿¡ »ç¿ëµÇ¾ú½À´Ï´Ù.

EIAÀÇ °³¹ß°ú ÃÖÀûÈ­´Â ±â¼úÀÇ »ý¹°ÇÐÀû Ãø¸é°ú °øÇÐÀû Ãø¸é ¸ðµÎ¿¡¼­ »ó´çÇÑ Àü¹®¼ºÀ» ÇÊ¿ä·Î ÇÕ´Ï´Ù. ³ôÀº ƯÀ̼º°ú ¹Î°¨µµ¸¦ È®º¸ÇÏ´Â °ÍÀº ƯÈ÷ »õ·Î¿î Ç¥ÀûÀ̳ª ºü¸£°Ô º¯ÀÌÇϴ ǥÀûÀÇ °æ¿ì ¾î·Á¿î °úÁ¦ÀÔ´Ï´Ù. »õ·Î¿î ºÐ¼®¿¡ ´ëÇÑ ±ÔÁ¦ ´ç±¹ÀÇ ½ÂÀÎÀ» ¹Þ´Â µ¥´Â ¸¹Àº ½Ã°£°ú ºñ¿ëÀÌ ¼Ò¿äµË´Ï´Ù. ±ÔÁ¦ ±âÁØÀº Áö¿ª¸¶´Ù Å©°Ô ´Ù¸£±â ¶§¹®¿¡ ÀÌ·¯ÇÑ ºÐ¼®ÀÇ Àü ¼¼°è À¯Åë°ú Ȱ¿ëÀ» º¹ÀâÇÏ°Ô ¸¸µì´Ï´Ù.

È¿¼Ò¸é¿ªÃøÁ¤¹ý ½ÃÀå º¸°í¼­ ÇÏÀ̶óÀÌÆ®

  • Á¦Ç°º°·Î´Â ½Ã¾à ¹× ŰƮ ºÐ¾ß°¡ 2023³â 67.5%ÀÇ Á¡À¯À²·Î ½ÃÀåÀ» Àå¾ÇÇß½À´Ï´Ù. ¼ºÀåÀÇ ¹è°æ¿¡´Â °¨¿°¼º ¹× ÀÚ°¡¸é¿ªÁúȯÀÇ À¯º´·ü Áõ°¡°¡ ÀÖ½À´Ï´Ù.
  • ¿ëµµº°·Î´Â °¨¿°¼º Áúȯ ºÐ¾ß°¡ 2023³â ½ÃÀåÀ» Àå¾ÇÇÏ°í ¿¹Ãø ±â°£ Áß °¡Àå ºü¸¥ CAGR·Î ¼ºÀåÇÒ °ÍÀ¸·Î ¿¹»óµË´Ï´Ù.
  • °Ëüº°·Î´Â Ç÷¾× °Ëü ºÎ¹®ÀÌ 2023³â ½ÃÀåÀ» Àå¾ÇÇß½À´Ï´Ù. ¼Òº¯ °Ëü ºÎ¹®Àº ¿¹Ãø ±â°£ Áß °¡Àå ºü¸¥ CAGR·Î ¼ºÀåÇÒ °ÍÀ¸·Î ¿¹»óµË´Ï´Ù.
  • ÃÖÁ¾ ¿ëµµº°·Î´Â º´¿ø ºÎ¹®ÀÌ 2023³â ½ÃÀåÀ» Àå¾ÇÇß½À´Ï´Ù.
  • ³ôÀº ±¸¸Å·Â Æò°¡, ¾çÁúÀÇ ÀÇ·á ¼­ºñ½º¿¡ ´ëÇÑ Á¤ºÎ Áö¿ø, »óȯ °¡´É¼º°ú °°Àº ¿äÀÎÀ¸·Î ÀÎÇØ 2023³â È¿¼Ò ¸é¿ª ÃøÁ¤¹ý ½ÃÀåÀº ºÏ¹Ì°¡ Áö¹èÀûÀ̾ú½À´Ï´Ù.

¸ñÂ÷

Á¦1Àå Á¶»ç ¹æ¹ý°ú ¹üÀ§

Á¦2Àå ÁÖ¿ä ¿ä¾à

Á¦3Àå ½ÃÀå º¯¼ö, µ¿Çâ, ¹üÀ§

  • ½ÃÀå °èÅë Àü¸Á
    • ¸ð½ÃÀå Àü¸Á
    • °ü·Ã/º¸Á¶ ½ÃÀå Àü¸Á
  • ½ÃÀå ¿ªÇÐ
    • ½ÃÀå ÃËÁø¿äÀÎ ºÐ¼®
    • ½ÃÀå ¾ïÁ¦¿äÀÎ ºÐ¼®
  • ¾÷°è ºÐ¼® Åø
    • Porter's Five Forces ºÐ¼®
    • PESTEL ºÐ¼®
    • COVID-19ÀÇ ¿µÇ⠺м®

Á¦4Àå È¿¼Ò¸é¿ªÃøÁ¤¹ý ½ÃÀå : Á¦Ç° ºñÁî´Ï½º ºÐ¼®

  • ºÎ¹® ´ë½Ãº¸µå
  • ¼¼°èÀÇ È¿¼Ò¸é¿ªÃøÁ¤¹ý ½ÃÀåÀÇ Á¦Ç° º¯µ¿ ºÐ¼®
  • ¼¼°èÀÇ È¿¼Ò¸é¿ªÃøÁ¤¹ý ½ÃÀå ±Ô¸ð¿Í µ¿Ç⠺м®, Á¦Ç°º°, 2018-2030³â
  • ½Ã¾à°ú ŰƮ
  • ºÐ¼®±â/°èÃø ±â±â
  • ¼ÒÇÁÆ®¿þ¾î¿Í ¼­ºñ½º

Á¦5Àå È¿¼Ò¸é¿ªÃøÁ¤¹ý ½ÃÀå : ¿ëµµ ºñÁî´Ï½º ºÐ¼®

  • ºÎ¹® ´ë½Ãº¸µå
  • ¼¼°èÀÇ È¿¼Ò¸é¿ªÃøÁ¤¹ý ½ÃÀåÀÇ ¿ëµµ, º¯µ¿ ºÐ¼®
  • ¼¼°èÀÇ È¿¼Ò¸é¿ªÃøÁ¤¹ý ½ÃÀå ±Ô¸ð¿Í µ¿Ç⠺м®, ¿ëµµº°, 2018-2030³â
  • Ä¡·áÁ¦ ¸ð´ÏÅ͸µ
  • Á¾¾çÇÐ
  • ½ÉÀ庴ÇÐ
  • ³»ºÐºñÇÐ
  • °¨¿°Áõ °Ë»ç
  • ÀÚ°¡¸é¿ªÁúȯ
  • ±âŸ

Á¦6Àå È¿¼Ò¸é¿ªÃøÁ¤¹ý ½ÃÀå : °Ëü ºñÁî´Ï½º ºÐ¼®

  • ºÎ¹® ´ë½Ãº¸µå
  • ¼¼°èÀÇ È¿¼Ò¸é¿ªÃøÁ¤¹ý ½ÃÀåÀÇ °Ëü º¯µ¿ ºÐ¼®
  • ¼¼°èÀÇ È¿¼Ò¸é¿ªÃøÁ¤¹ý ½ÃÀå ±Ô¸ð¿Í µ¿Ç⠺м®, °Ëüº°, 2018-2030³â
  • Ç÷¾×
  • Ÿ¾×
  • ´¢
  • ±âŸ °Ëü

Á¦7Àå È¿¼Ò¸é¿ªÃøÁ¤¹ý ½ÃÀå : ÃÖÁ¾ ¿ëµµ ºñÁî´Ï½º ºÐ¼®

  • ºÎ¹® ´ë½Ãº¸µå
  • ¼¼°èÀÇ È¿¼Ò¸é¿ªÃøÁ¤¹ý ½ÃÀåÀÇ ÃÖÁ¾ ¿ëµµ º¯µ¿ ºÐ¼®
  • ¼¼°èÀÇ È¿¼Ò¸é¿ªÃøÁ¤¹ý ½ÃÀå ±Ô¸ð¿Í µ¿Ç⠺м®, ÃÖÁ¾ ¿ëµµº°, 2018-2030³â
  • º´¿ø
  • Ç÷¾×ÀºÇà
  • ÀÓ»ó °Ë»ç½Ç
  • Á¦¾à¡¤¹ÙÀÌ¿ÀÅ×Å©³î·¯Áö ±â¾÷
  • Çмú¿¬±¸ ¼¾ÅÍ
  • ±âŸ

Á¦8Àå È¿¼Ò¸é¿ªÃøÁ¤¹ý ½ÃÀå : Á¦Ç°, ¿ëµµ, °Ëü, ÃÖÁ¾ ¿ëµµº° Áö¿ª ÃßÁ¤¡¤µ¿Ç⠺м®

  • Áö¿ª ´ë½Ãº¸µå
  • ½ÃÀå ±Ô¸ð¿Í ¿¹Ãø ¹× µ¿Ç⠺м®, 2018-2030³â
  • ºÏ¹Ì
  • À¯·´
  • ¾Æ½Ã¾ÆÅÂÆò¾ç
  • ¶óƾ¾Æ¸Þ¸®Ä«
  • Áßµ¿ ¹× ¾ÆÇÁ¸®Ä«

Á¦9Àå °æÀï ±¸µµ

  • Âü¿© ±â¾÷
  • Àü·« ¸ÅÇÎ
  • ±â¾÷ ½ÃÀå ÇöȲ ºÐ¼®, 2023³â
  • Âü¿© ±â¾÷ÀÇ °³¿ä
    • Siemens Healthineers
    • Danaher Corporation(Beckman Coulter)
    • bioMerieux SA
    • Sysmex Corporation
    • QuidelOrtho Corporation.
    • Bio-Rad Laboratories, Inc.
    • F. Hoffmann-La Roche AG
    • Becton, Dickinson, and Company
    • Thermo Fisher Scientific, Inc.
KSA 24.06.21

Enzyme Immunoassay Market Growth & Trends:

The global enzyme immunoassay market size is anticipated to reach USD 22.42 billion by 2030, expanding at a CAGR of 3.9% from 2024 to 2030, according to a new report by Grand View Research, Inc. Increasing prevalence of chronic and infectious diseases, rising demand for point-of-care testing, and growing awareness and healthcare expenditure are expected to boost the market further. Moreover, the increasing number of joint ventures, product launches amongst market players and rising government investment is also expected to have a positive impact on market growth. For instance, in July 2023, Anbio Biotechnology Limited launched the AF-100S FIA Solution, a handheld solution for point-of-care immunodiagnostics. This analyzer can detect a broad spectrum of analyte enzymes and perform up to 240 tests per hour.

Rising government investment is expected to significantly support the market growth of enzyme immunoassay technologies. Government investments aid in the expansion of healthcare infrastructure, primarily in developing countries. This expansion helps in the wider adoption and integration of EIA technologies in clinical settings, enhancing the capacity for early disease detection, monitoring, and management. It also facilitates the establishment of national health programs that can use EIAs for large-scale screening and surveillance activities, such as infectious disease control and prevention programs. For instance, in March 2022, the UK government announced an investment of USD 347 million to enhance research and development and the production of novel devices and diagnostics.

The COVID-19 pandemic had a significant impact on the market. The pandemic caused disturbances in the supply chain and manufacturing processes of various healthcare products, including EIA kits and reagents. These disruptions were due to lockdown measures, labor shortages, and logistical challenges. However, the pandemic impacted the market by accelerating the development and adoption of EIA technologies for the detection of SARS-CoV-2 antibodies. This surge in demand was driven by the need for mass testing to identify infected individuals and understand the spread of the virus. Enzyme immunoassays, known for their specificity and sensitivity, became vital tools in the fight against the pandemic, used for diagnosing active infections and studies to assess the extent of virus spread within populations.

The development and optimization of EIAs require significant expertise in both the biological and engineering aspects of the technology. Ensuring high specificity and sensitivity can be challenging, especially for novel or rapidly mutating targets. Obtaining regulatory approval for new assays is a lengthy and expensive process. Regulatory standards can vary significantly between different regions, complicating the global distribution and use of these assays.

Enzyme Immunoassay Market Report Highlights:

  • Based on product, the reagents and kits segment dominated the market with a share of 67.5% in 2023. The growth is attributed to the rising prevalence of infectious and autoimmune diseases
  • Based on application, the infectious diseases segment dominated the market in 2023 and is expected to grow at the fastest CAGR over the forecast period
  • Based on specimen, the blood specimen segment dominated the market in 2023. The urine specimen segment is anticipated to grow at the fastest CAGR over the forecast period
  • Based on end-use, the hospitals segment dominated the market in 2023
  • North America dominated the enzyme immunoassay market in 2023 owing to factors such as the high purchasing power parity, government support for quality healthcare, and availability of reimbursement

Table of Contents

Chapter 1. Methodology and Scope

  • 1.1. Market Segmentation and Scope
  • 1.2. Market Definitions
    • 1.2.1. Product
    • 1.2.2. Application
    • 1.2.3. Speicmen
    • 1.2.4. End-use
  • 1.3. Information analysis
  • 1.4. Market formulation & data visualization
  • 1.5. Data validation & publishing
  • 1.6. Information Procurement
    • 1.6.1. Primary Research
  • 1.7. Information or Data Analysis
  • 1.8. Market Formulation & Validation
  • 1.9. Market Model
  • 1.10. Objectives

Chapter 2. Executive Summary

  • 2.1. Market Outlook
  • 2.2. Segment Snapshot
  • 2.3. Competitive Landscape Snapshot

Chapter 3. Market Variables, Trends, & Scope

  • 3.1. Market Lineage Outlook
    • 3.1.1. Parent Market Outlook
    • 3.1.2. Related/Ancillary Market Outlook
  • 3.2. Market Dynamics
    • 3.2.1. Market Driver Analysis
      • 3.2.1.1. Rising incidence of chronic and infectious diseases
      • 3.2.1.2. Increasing demand for point-of-care diagnostics
      • 3.2.1.3. Growing demand for portable and automated immunoassays
    • 3.2.2. Market Restraint Analysis
      • 3.2.2.1. Lower detection limit
      • 3.2.2.2. Limitations associated with immunoassay techniques
  • 3.3. Industry Analysis Tools
    • 3.3.1. Porter's Five Forces Analysis
    • 3.3.2. PESTEL Analysis
    • 3.3.3. COVID-19 Impact Analysis

Chapter 4. Enzyme Immunoassay Market: Product Business Analysis

  • 4.1. Segment Dashboard
  • 4.2. Global Enzyme Immunoassay Market Product Movement Analysis
  • 4.3. Global Enzyme Immunoassay Market Size & Trend Analysis, by Product, 2018 to 2030 (USD Million)
  • 4.4. Reagents & Kits
    • 4.4.1. Global Reagents & Kits Market Estimates and Forecasts, 2018 - 2030 (USD Million)
  • 4.5. Analyzers/Instruments
    • 4.5.1. Global Analyzers/Instruments Market Estimates and Forecasts, 2018 - 2030 (USD Million)
  • 4.6. Software & Services
    • 4.6.1. Global Software & Services Market Estimates and Forecasts, 2018 - 2030 (USD Million)

Chapter 5. Enzyme Immunoassay Market: Application Business Analysis

  • 5.1. Segment Dashboard
  • 5.2. Global Enzyme Immunoassay Market Application, Movement Analysis
  • 5.3. Global Enzyme Immunoassay Market Size & Trend Analysis, by Application, 2018 to 2030 (USD Million)
  • 5.4. Therapeutic Drug Monitoring
    • 5.4.1. Global Therapeutic Drug Monitoring Market Estimates and Forecasts, 2018 - 2030 (USD Million)
  • 5.5. Oncology
    • 5.5.1. Global Oncology Market Estimates and Forecasts, 2018 - 2030 (USD Million)
  • 5.6. Cardiology
    • 5.6.1. Global Cardiology Market Estimates and Forecasts, 2018 - 2030 (USD Million)
  • 5.7. Endocrinology
    • 5.7.1. Global Endocrinology Market Estimates and Forecasts, 2018 - 2030 (USD Million)
  • 5.8. Infectious Disease Testing
    • 5.8.1. Global Infectious Disease Testing Market Estimates and Forecasts, 2018 - 2030 (USD Million)
  • 5.9. Autoimmune Diseases
    • 5.9.1. Global Autoimmune Diseases Market Estimates and Forecasts, 2018 - 2030 (USD Million)
  • 5.10. Others
    • 5.10.1. Others Market Estimates and Forecasts, 2018 - 2030 (USD Million)

Chapter 6. Enzyme Immunoassay Market: Specimen Business Analysis

  • 6.1. Segment Dashboard
  • 6.2. Global Enzyme Immunoassay Market Specimen Movement Analysis
  • 6.3. Global Enzyme Immunoassay Market Size & Trend Analysis, by Specimen, 2018 to 2030 (USD Million)
  • 6.4. Blood
    • 6.4.1. Global Blood Market Estimates and Forecasts, 2018 - 2030 (USD Million)
  • 6.5. Saliva
    • 6.5.1. Global Saliva Market Estimates and Forecasts, 2018 - 2030 (USD Million)
  • 6.6. Urine
    • 6.6.1. Global Urine Market Estimates and Forecasts, 2018 - 2030 (USD Million)
  • 6.7. Other Specimens
    • 6.7.1. Global Other Specimens Market Estimates and Forecasts, 2018 - 2030 (USD Million)

Chapter 7. Enzyme Immunoassay Market: End-use Business Analysis

  • 7.1. Segment Dashboard
  • 7.2. Global Enzyme Immunoassay Market End-use Movement Analysis
  • 7.3. Global Enzyme Immunoassay Market Size & Trend Analysis, by End-use, 2018 to 2030 (USD Million)
  • 7.4. Hospitals
    • 7.4.1. Global Hospitals Market Estimates and Forecasts, 2018 - 2030 (USD Million)
  • 7.5. Blood Banks
    • 7.5.1. Global Blood Banks Market Estimates and Forecasts, 2018 - 2030 (USD Million)
  • 7.6. Clinical Laboratories
    • 7.6.1. Global Clinical Laboratories Market Estimates and Forecasts, 2018 - 2030 (USD Million)
  • 7.7. Pharmaceutical and Biotech Companies
    • 7.7.1. Global Pharmaceutical and Biotech Companies Market Estimates and Forecasts, 2018 - 2030 (USD Million)
  • 7.8. Academic Research Centers
    • 7.8.1. Global Academic Research Centers Market Estimates and Forecasts, 2018 - 2030 (USD Million)
  • 7.9. Others
    • 7.9.1. Global Others Market Estimates and Forecasts, 2018 - 2030 (USD Million)

Chapter 8. Enzyme Immunoassay Market: Regional Estimates & Trend Analysis by Product, Application, Specimen & End-use

  • 8.1. Regional Dashboard
  • 8.2. Market Size & Forecasts and Trend Analysis, 2018 to 2030
  • 8.3. North America
    • 8.3.1. North America Enzyme Immunoassay Market Estimates and Forecasts, 2018 - 2030 (USD Million)
    • 8.3.2. U.S.
      • 8.3.2.1. Key Country Dynamics
      • 8.3.2.2. Competitive Scenario
      • 8.3.2.3. Regulatory Framework
      • 8.3.2.4. U.S. Enzyme Immunoassay Market Estimates and Forecasts, 2018 - 2030 (USD Million)
    • 8.3.3. Canada
      • 8.3.3.1. Key Country Dynamics
      • 8.3.3.2. Competitive Scenario
      • 8.3.3.3. Regulatory Framework
      • 8.3.3.4. Canada Enzyme Immunoassay Market Estimates and Forecasts, 2018 - 2030 (USD Million)
  • 8.4. Europe
    • 8.4.1. Europe Enzyme Immunoassay Market Estimates and Forecasts, 2018 - 2030 (USD Million)
    • 8.4.2. UK
      • 8.4.2.1. Key Country Dynamics
      • 8.4.2.2. Competitive Scenario
      • 8.4.2.3. Regulatory Framework
      • 8.4.2.4. UK Enzyme Immunoassay Market Estimates and Forecasts, 2018 - 2030 (USD Million)
    • 8.4.3. Germany
      • 8.4.3.1. Key Country Dynamics
      • 8.4.3.2. Competitive Scenario
      • 8.4.3.3. Regulatory Framework
      • 8.4.3.4. Germany Enzyme Immunoassay Market Estimates and Forecasts, 2018 - 2030 (USD Million)
    • 8.4.4. France
      • 8.4.4.1. Key Country Dynamics
      • 8.4.4.2. Competitive Scenario
      • 8.4.4.3. Regulatory Framework
      • 8.4.4.4. France Enzyme Immunoassay Market Estimates and Forecasts, 2018 - 2030 (USD Million)
    • 8.4.5. Italy
      • 8.4.5.1. Key Country Dynamics
      • 8.4.5.2. Competitive Scenario
      • 8.4.5.3. Regulatory Framework
      • 8.4.5.4. Italy Enzyme Immunoassay Market Estimates and Forecasts, 2018 - 2030 (USD Million)
    • 8.4.6. Spain
      • 8.4.6.1. Key Country Dynamics
      • 8.4.6.2. Competitive Scenario
      • 8.4.6.3. Regulatory Framework
      • 8.4.6.4. Spain Enzyme Immunoassay Market Estimates and Forecasts, 2018 - 2030 (USD Million)
    • 8.4.7. Denmark
      • 8.4.7.1. Key Country Dynamics
      • 8.4.7.2. Competitive Scenario
      • 8.4.7.3. Regulatory Framework
      • 8.4.7.4. Denmark Enzyme Immunoassay Market Estimates and Forecasts, 2018 - 2030 (USD Million)
    • 8.4.8. Sweden
      • 8.4.8.1. Key Country Dynamics
      • 8.4.8.2. Competitive Scenario
      • 8.4.8.3. Regulatory Framework
      • 8.4.8.4. Sweden Enzyme Immunoassay Market Estimates and Forecasts, 2018 - 2030 (USD Million)
    • 8.4.9. Norway
      • 8.4.9.1. Key Country Dynamics
      • 8.4.9.2. Competitive Scenario
      • 8.4.9.3. Regulatory Framework
      • 8.4.9.4. Norway Enzyme Immunoassay Market Estimates and Forecasts, 2018 - 2030 (USD Million)
  • 8.5. Asia Pacific
    • 8.5.1. Asia Pacific Enzyme Immunoassay Market Estimates and Forecasts, 2018 - 2030 (USD Million)
    • 8.5.2. Japan
      • 8.5.2.1. Key Country Dynamics
      • 8.5.2.2. Competitive Scenario
      • 8.5.2.3. Regulatory Framework
      • 8.5.2.4. Japan Enzyme Immunoassay Market Estimates and Forecasts, 2018 - 2030 (USD Million)
    • 8.5.3. China
      • 8.5.3.1. Key Country Dynamics
      • 8.5.3.2. Competitive Scenario
      • 8.5.3.3. Regulatory Framework
      • 8.5.3.4. China Enzyme Immunoassay Market Estimates and Forecasts, 2018 - 2030 (USD Million)
    • 8.5.4. India
      • 8.5.4.1. Key Country Dynamics
      • 8.5.4.2. Competitive Scenario
      • 8.5.4.3. Regulatory Framework
      • 8.5.4.4. India Enzyme Immunoassay Market Estimates and Forecasts, 2018 - 2030 (USD Million)
    • 8.5.5. Australia
      • 8.5.5.1. Key Country Dynamics
      • 8.5.5.2. Competitive Scenario
      • 8.5.5.3. Regulatory Framework
      • 8.5.5.4. Australia Enzyme Immunoassay Market Estimates and Forecasts, 2018 - 2030 (USD Million)
    • 8.5.6. Thailand
      • 8.5.6.1. Key Country Dynamics
      • 8.5.6.2. Competitive Scenario
      • 8.5.6.3. Regulatory Framework
      • 8.5.6.4. Thailand Enzyme Immunoassay Market Estimates and Forecasts, 2018 - 2030 (USD Million)
    • 8.5.7. South Korea
      • 8.5.7.1. Key Country Dynamics
      • 8.5.7.2. Competitive Scenario
      • 8.5.7.3. Regulatory Framework
      • 8.5.7.4. South Korea Enzyme Immunoassay Market Estimates and Forecasts, 2018 - 2030 (USD Million)
  • 8.6. Latin America
    • 8.6.1. Latin America Enzyme Immunoassay Market Estimates and Forecasts, 2018 - 2030 (USD Million)
    • 8.6.2. Brazil
      • 8.6.2.1. Key Country Dynamics
      • 8.6.2.2. Competitive Scenario
      • 8.6.2.3. Regulatory Framework
      • 8.6.2.4. Brazil Enzyme Immunoassay Market Estimates and Forecasts, 2018 - 2030 (USD Million)
    • 8.6.3. Mexico
      • 8.6.3.1. Key Country Dynamics
      • 8.6.3.2. Competitive Scenario
      • 8.6.3.3. Regulatory Framework
      • 8.6.3.4. Mexico Enzyme Immunoassay Market Estimates and Forecasts, 2018 - 2030 (USD Million)
    • 8.6.4. Argentina
      • 8.6.4.1. Key Country Dynamics
      • 8.6.4.2. Competitive Scenario
      • 8.6.4.3. Regulatory Framework
      • 8.6.4.4. Argentina Enzyme Immunoassay Market Estimates and Forecasts, 2018 - 2030 (USD Million)
  • 8.7. MEA
    • 8.7.1. MEA Enzyme Immunoassay Market Estimates and Forecasts, 2018 - 2030 (USD Million)
    • 8.7.2. South Africa
      • 8.7.2.1. Key Country Dynamics
      • 8.7.2.2. Competitive Scenario
      • 8.7.2.3. Regulatory Framework
      • 8.7.2.4. South Africa Enzyme Immunoassay Market Estimates and Forecasts, 2018 - 2030 (USD Million)
    • 8.7.3. Saudi Arabia
      • 8.7.3.1. Key Country Dynamics
      • 8.7.3.2. Competitive Scenario
      • 8.7.3.3. Regulatory Framework
      • 8.7.3.4. Saudi Arabia Enzyme Immunoassay Market Estimates and Forecasts, 2018 - 2030 (USD Million)
    • 8.7.4. UAE
      • 8.7.4.1. Key Country Dynamics
      • 8.7.4.2. Competitive Scenario
      • 8.7.4.3. Regulatory Framework
      • 8.7.4.4. UAE Enzyme Immunoassay Market Estimates and Forecasts, 2018 - 2030 (USD Million)
    • 8.7.5. Kuwait
      • 8.7.5.1. Key Country Dynamics
      • 8.7.5.2. Competitive Scenario
      • 8.7.5.3. Regulatory Framework
      • 8.7.5.4. Kuwait Enzyme Immunoassay Market Estimates and Forecasts, 2018 - 2030 (USD Million)

Chapter 9. Competitive Landscape

  • 9.1. Participant Categorization
  • 9.2. Strategy Mapping
  • 9.3. Company Market Position Analysis, 2023
  • 9.4. Participant's Overview
    • 9.4.1. Siemens Healthineers
      • 9.4.1.1. Overview
      • 9.4.1.2. Financial Performance
      • 9.4.1.3. Product Benchmarking
      • 9.4.1.4. Strategic Initiatives
    • 9.4.2. Danaher Corporation (Beckman Coulter)
      • 9.4.2.1. Overview
      • 9.4.2.2. Financial Performance
      • 9.4.2.3. Product Benchmarking
      • 9.4.2.4. Strategic Initiatives
    • 9.4.3. bioMerieux SA
      • 9.4.3.1. Overview
      • 9.4.3.2. Financial Performance
      • 9.4.3.3. Product Benchmarking
      • 9.4.3.4. Strategic Initiatives
    • 9.4.4. Sysmex Corporation
      • 9.4.4.1. Overview
      • 9.4.4.2. Financial Performance
      • 9.4.4.3. Product Benchmarking
      • 9.4.4.4. Strategic Initiatives
    • 9.4.5. QuidelOrtho Corporation.
      • 9.4.5.1. Overview
      • 9.4.5.2. Financial Performance
      • 9.4.5.3. Product Benchmarking
      • 9.4.5.4. Strategic Initiatives
    • 9.4.6. Bio-Rad Laboratories, Inc.
      • 9.4.6.1. Overview
      • 9.4.6.2. Financial Performance
      • 9.4.6.3. Product Benchmarking
      • 9.4.6.4. Strategic Initiatives
    • 9.4.7. F. Hoffmann-La Roche AG
      • 9.4.7.1. Overview
      • 9.4.7.2. Financial Performance
      • 9.4.7.3. Product Benchmarking
      • 9.4.7.4. Strategic Initiatives
    • 9.4.8. Becton, Dickinson, and Company
      • 9.4.8.1. Overview
      • 9.4.8.2. Financial Performance
      • 9.4.8.3. Product Benchmarking
      • 9.4.8.4. Strategic Initiatives
    • 9.4.9. Thermo Fisher Scientific, Inc.
      • 9.4.9.1. Overview
      • 9.4.9.2. Financial Performance
      • 9.4.9.3. Product Benchmarking
      • 9.4.9.4. Strategic Initiatives
ºñ±³¸®½ºÆ®
0 °ÇÀÇ »óǰÀ» ¼±Åà Áß
»óǰ ºñ±³Çϱâ
Àüü»èÁ¦